For example, therapeutic agents targeting inflammation and fibrosis in NASH, CCR2/CCR5, TLR4, ASK1 and lysine oxidase were considered ineffective in recent clinical trials to alleviate endpoint outcomes in NASH, particularly fibrosis [10, 338]. This evidence concerns the gene CCR5 and metabolic dysfunction-associated steatohepatitis.